Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01714583 · ClinicalTrials.gov registry record
The Relationship Between Positive End Expiratory Pressure and Cardiac Index in Patients With Acute Respiratory Distress Syndrome (ARDS) Managed on a Fluid Protocol
A clinical trial of Acute Respiratory Distress Syndrome (ARDS), sponsored by Yale University.
- Completed
- Registry status
- 367
- Enrollment target
- 1
- Study location
NCT01714583 is a study of Acute Respiratory Distress Syndrome (ARDS) that has completed, run by Yale University. The registered enrollment target is 367 participants, below the 17,689-participant average among 8 other Acute Respiratory Distress Syndrome (ARDS) trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01714583, a study of Acute Respiratory Distress Syndrome (ARDS), has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 367 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to evaluate the association between positive end-expiratory pressure (PEEP) setting and cardiac function, as measured by cardiac index, in patients with acute respiratory distress syndrome (ARDS) who were managed on the NHLBI ARDS Network Fluid and Catheter Treatment Trial (FACTT) fluid protocols.
Conditions Studied
Study Locations (1)
Connecticut
- Yale University, School of Medicine, Department of Internal Medicine, Section of Pulmonary and Critical Care Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 367 participants |
| Start Date | 2011-04 |
| Est. Completion | 2012-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01714583
The ClinicalTrials.gov registry entry for NCT01714583 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 367 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 17,689-participant average among 8 other Acute Respiratory Distress Syndrome (ARDS) trials with a reported enrollment target (98% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Respiratory Distress Syndrome (ARDS) appearing as the primary indexed condition, and to 0 interventions.
NCT01714583 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT01714583 about?
NCT01714583 is a clinical study titled "The Relationship Between Positive End Expiratory Pressure and Cardiac Index in Patients With Acute Respiratory Distress Syndrome (ARDS) Managed on a Fluid Protocol". The objective of this study is to evaluate the association between positive end-expiratory pressure (PEEP) setting and cardiac function, as measured by cardiac index, in patients with acute respiratory distress syndrome (ARDS) who were managed on the NHLBI ARDS Network Fluid and Catheter Treatment T...
What is the current status of trial NCT01714583?
This trial is currently completed. The enrollment target is 367 participants. The study started on 2011-04. Estimated completion is 2012-09.
What conditions does trial NCT01714583 study?
This clinical trial studies the following conditions: Acute Respiratory Distress Syndrome (ARDS).
Who is sponsoring clinical trial NCT01714583?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01714583 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Respiratory Distress Syndrome (ARDS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
RECRUITING · Phase 2
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
RECRUITING · Phase 2
-
Pediatric Acute Respiratory Distress Syndrome (ARDS) Management Trial
RECRUITING · Phase 2
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
RECRUITING · Phase 2
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
RECRUITING · Phase 2
-
An Observational Study to Identify New Health Problems Arising After an Intensive Care Unit Admission in People With Acute Respiratory Distress Syndrome in the United States
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.